Serum Institute of India says ‘will resume Covid vaccine trials’ after drug controller’s nod
Team Udayavani, Sep 13, 2020, 9:56 AM IST
New Delhi: Serum Institute of India will resume clinical trials of AstraZeneca’s COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI), the Pune-based vaccine maker said on Saturday.
Pharma giant AstraZeneca on Saturday said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials were safe.
“Once DCGI will give us the permission to restart the trials in India, we will resume the trials,” Serum Institute of India (SII) said in a statement.
In a tweet, SII CEO Adar Poonawalla said: “As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events is a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford.”
The human trials resumed days after a pause had been announced in the trials after an adverse reaction in one of the participants.
Following the suspension, the DCGI directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the vaccine candidate.
AstraZeneca and the University of Oxford, as the trial sponsor, on Saturday said that they cannot disclose further medical information but confirmed that independent investigations concluded that the trials were safe to restart.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
ISRO releases ISSAR 2023 report on vulnerability of space assets to collisions
No CM can remain absent for long, it’s against national interest: Delhi HC on Kejriwal
Court convicts four accused, acquits 10 in 2015 Malvani hooch tragedy
ICG apprehends Indian fishing boat with 173 kg of narcotics; two crew members detained
Ahead of phase 3 polls, Congress and BJP spar in MP over quotas, Muslim appeasement
MUST WATCH
Latest Additions
ISRO releases ISSAR 2023 report on vulnerability of space assets to collisions
Hunasagi: MLA Bairati Basavaraj’s car overturned
No CM can remain absent for long, it’s against national interest: Delhi HC on Kejriwal
Cricket for the Blind: A Transformative Journey Empowering Visually Impaired Athletes
China lifts restrictions, gives all clear nod for Tesla cars as Musk lobbies hard in surprise visit to Beijing